Stacy Dixon, MD, PhD

Publications

• Hunn SM, Alfano LN, Jones A, Butler A, Lowes LP, Iammarino MA, Reash NF, Pietruszewski L, Sasidharan S, Currence M, Statland JM, Strahler T, Will R, Wicklund M, Dixon S, Augsburger R, Mozaffar T, Laubscher KM, Mockler SRH, Mathews KD, Stinson N, Leung DG, Stark MM, Horton RA, Kang PB, James MK, Clause A, Weihl CC, Johnson NE. Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study. Ann Clin Transl Neurol. 2025 Jun;12(6):1179-1186. PubMed PMID: 40237364
• Adams D, Wixner J, Polydefkis M, Berk JL, Conceição IM, Dispenzieri A, Peltier A, Ueda M, Bender S, Capocelli K, Jay PY, Yureneva E, Obici L. Five-Year Results With Patisiran for Hereditary Transthyretin Amyloidosis With Polyneuropathy: A Randomized Clinical Trial With Open-Label Extension. JAMA Neurol. 2025 Mar 1;82(3):228-236. PubMed PMID: 39804640
• Arya K, Chiriboga CA, Dixon S, Hamid OA, Kumar A, Ladha S, Matesanz SE, Richardson RC, Scharf R, Varadhachary AS, Wright SE, Tanvir I, Lim E, Keto E, Shah R, and WeSMA Study Group, “A long-term follow-up study of ridsiplam (WeSMA study): interim results in adult participants with SMA.” Cure SMA Annual Research & Clinical Care Meeting, Anaheim, CA (June 2025, poster presentation).
• Walker M, Butterfield R, Clay R, Day J, Dixon S, Eichinger K, Elsheikh B, Friedman S, Genge A, Hewamadduma C, Johnson N, Jones P, Leung D, Lewis L, Lochmuller H, O’Ferral E, Martens W, Shaw D, Shieh P, Subramon S, Trivedi J, Wang L, Wicklund M, Tawil R, Statland J, and MOVE FSHD Investigators and study teams of the FSHD CTRN, “Motor Outcomes to Validate Evaluations in Facioscapulohumeral muscular dystrophy (MOVE FSHD): Interim Baseline Data and Potential Predictors for FSHD,” International Research Congress – FSHD Society, Amsterdam, Netherlands (June 2025, poster presentation)
• Arya K, Chiriboga CA, Dixon S, Hamid OA, Kumar A, Ladha S, Matesanz SE, Richardson RC, Scharf R, Varadhachary AS, Wright SE, Tanvir I, Lim E, Keto E, Shah R, and WeSMA Study Group, “A long-term follow-up study of ridsiplam (WeSMA study): Interim results in adult participants with SMA.” AANEM 2025 Annual Meeting, San Francisco, CA (October 2025, poster presentation)
• Doody A, Alfano L, Diaz-Manera J, Lowes L, Mozaffar T, Mathews KD, Weihl CC, Wicklund M, Hung M, Statland J, Johnson NE. Defining clinical endpoints in limb girdle muscular dystrophy: a GRASP-LGMD study. BMC Neurol. 2024 Mar 15;24(1):96. PubMed PMID: 38491364
• Phillips J, Dixon S, Koehler T, Kluger B. Advance Care Planning Among Patients With Amyotrophic Lateral Sclerosis: Patient Perspectives on Goals of Care Conversations. Am J Hosp Palliat Care. 2024 Mar;41(3):295-301. PubMed PMID: 37128837
• Herrera M, Wencel M, Hernandez I, Goyal NA, Dimachkie M, Lloyd T, Mohassel P, Weihl C, Freimer M, Shaibani A, Wicklund M, Dixon S, Chahin N, Wang L, Shieh P, Amato A, Quinn C, Carbunar O, Barohn R, Herbelin L, Mozaffar T, and INSPIRE-IBM Study Group. "Investigating Functional Difference in NT5c1A Seropositive and Seronegative IBM Participants in the INSPIRE-IBM Study Trial." Neuromuscular Study Group Annual Scientific Meeting, Tarrytown, NY (September 2024). Poster presentation.
• Gaid P, Wencel M, Hernandez I, Goyal NA, Dimachkie M, Lloyd T, Mohassel P, Weihl C, Freimer M, Shaibani A, Wicklund M, Dixon S, Chahin N, Wang L, Shieh P, Amato A, Quinn C, Carbunar O, Barohn R, Herbelin L, Mozaffar T, and INSPIRE-IBM Study Group. "Comparing IBMFRS and sIFA as Progression Indicators in Inclusion Body Myositis Patients from the INSPIRE IBM Trial." Neuromuscular Study Group Annual Scientifc Meeting, Tarrytown, NY (September 2024). Poster presentation.
• Herrera M, Wencel M, Matthew S, Goyal NA, Dimachkie M, Lloyd T, Mohassel P, Weihl C, Freimer M, Shaibani A, Wicklund M, Dixon S, Chahin N, Wang L, Shieh P, Amato A, Quinn C, Carbunar O, Mozaffar T, and INSPIRE-IBM Study Group. "Investigating Functional Difference in NT5c1A Seropositive and Seronegative IBM Participants in the INSPIRE-IBM Study Trial." MDA Clinical and Scientific Conference, Orlando, FL. Poster presentation.
• Walker M, Hewamadduma C, Butterfield R, Day J, Dixon S, Eichinger K, Elsheikh B, Friedman S, Genge A, Johnson N, Jones P, Leung D, Lewis L, Lochmuller H, O'Ferrall E, Martens W, Shaw D, Shieh P, Subramony S, Trivedi J, Wang L, Wicklund M, Tawil R, Statland J, and the MOVE FSHD Investigators and study teams of the FSHD CTRN. "Motor Outcomes to Validate Evaluations in Facioscapulohumeral muscular dystrophy (MOVE FSHD): Interim Baseline Data and Potential Predictors for FSHD." MDA Clinical and Scientific Conference, Orlando, FL. Poster presentation.
• Bjazevic K, Wencel M, Matthews S, Goyal NA, Dimachkie, M, Lloyd T, Mohassel P, Weihl C, Freimer M, Shaibani A, Wicklund M, Dixon S, Chahin N, Wang L, Shieh P, Amato A, Quinn C, Carbunar O, Mozaffar T, and INSPIRE-IBM Study Group. "Comparative Evaluation of Pulmonary Function Tests in IBM based on Serology to NT5c1A Antibodies." MDA Clinical and Scientific Conference, Orlando, FL. Poster presentation.
• Gaid P, Wencel M, Matthew S, Goyal NA, Dimachkie, M, Lloyd T, Mohassel P, Weihl C, Freimer M, Shaibani A, Wicklund M, Dixon S, Chahin N, Wang L, Shieh P, Amato A, Quinn C, Carbunar O, Mozaffar T, and INSPIRE-IBM Study Group. "Comparative Analysis of PFTs and PROMIS Dyspnea in the INSPIRE IBM Trial." MDA Clinical and Scientific Conference, Orlando, FL. Poster presentation.
• Gaid P, Wencel M, Matthew S, Goyal NA, Dimachkie, M, Lloyd T, Mohassel P, Weihl C, Freimer M, Shaibani A, Wicklund M, Dixon S, Chahin N, Wang L, Shieh P, Amato A, Quinn C, Carbunar O, Mozaffar T, and INSPIRE-IBM Study Group. "Assessing PROMIS Pain Measures Across Various Disease Durations in IBM Patients from the INSPIRE IBM Trial." MDA Clinical and Scientific Conference, Orlando, FL. Poster presentation.
• Phillips J, Dixon S, Koehler T, Kluger B. Advance Care Planning Among Patients With Amyotrophic Lateral Sclerosis: Patient Perspectives on Goals of Care Conversations. Am J Hosp Palliat Care. 2023 Apr 27;:10499091231172901. [Epub ahead of print] PubMed PMID: 37128837
• Meisel A, Annane D, Vu T, Mantegazza R, Katsuno M, Aguzzi R, Frick G, Gault L, Howard JF Jr. Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension. J Neurol. 2023 Aug;270(8):3862-3875. PubMed PMID: 37103755
• Lafreniere M, Dixon SE, Kammeyer R, Declusin A, “Cognitive changes, weakness, and myoclonus in a 78-year old man: a case presentation.” Carrell-Krusen Neuromuscular Symposium, Dallas, TX (February 2023, poster presentation).
• Dixon S, Kang X, Quan, D. Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis. Therapeutics and Clinical Risk Management 2023:19 973–981.
• Vu T, Meisel A, Mantegazza R, Annane D, Katsuno M, Aguzzi R, Enayetallah A, Beasley KN, Rampal N, Howard JF, CHAMPION MG Study Group. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid. 2022; 1 (5)
• Lafreniere M, Dixon SE, “Thoughts and Perceptions of Risdiplam from Adults with SMA.” CureSMA Researcher and Clinical Care Meeting, Anaheim, CA (June 2022, Poster presentation).
• Petluru M, Dixon SE, “Worsening Upper Extremity Weakness Seen as a Side Effect of Risdiplam in Adults with Spinal Muscular Atrophy.” CureSMA Researcher and Clinical Care Meeting, Anaheim, CA (June 2022, Poster presentation).
• Chen E., Dixon, S.E., Naik, R., Noone, J., Buchenberger, D., Whitmire, S., Mills, R., Arnold, W. (2021). Early experiences in the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers. Muscle & Nerve, 63(13), 311-319.
• Monnette, A., Chen, E., Hong, D., Bazzano, A., Dixon, S.E., Arnold, WD., Shi, L. (2021). Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet Journal of Rare Diseases, 20;16(1):36
• Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH 3rd, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T; patisiran Global OLE study group. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021 Jan;20(1):49-59.
• Chen E, Dixon S, Naik R, Noone JM, Buchenberger JD, Whitmire SM, Mills R, Arnold W. Early experiences of nusinersen for the treatment of spinal muscular atrophy: Results from a large survey of patients and caregivers. Muscle Nerve. 2021 Mar;63(3):311-319. PubMed PMID: 33184859
• Monnette A, Chen E, Hong D, Bazzano A, Dixon S, Arnold WD, Shi L. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021 Jan 20;16(1):36. PubMed PMID: 33472673
• Poe, J., Lozowska, D., & Dixon, S. (2019). Statin Autoimmune Necrotizing Myopathy Diagnosed After a Motor Vehicle Accident. Marshall Journal of Medicine, 5(1), 6.
• Dixon SE and Quan D. “Electromyography and nerve conduction studies.” In: West SG, Kolfenbach JR, eds., Rheumatology Secrets, 4th edition. Philadelphia: Elsevier Mosby, 2019, pp. 85-88.
• Wilson Z and Dixon SE, “Appropriate Pain Management Following Open Muscle.” Carrell-Krusen Neuromuscular Symposium, Dallas, TX (Feb 2019, Poster presentation).
• Kang X, Fridman V, and Dixon SE, “Two Interesting Cases of Fiber Type Disproportion”. Carrell-Krusen Neuromuscular Symposium, Dallas, TX (Feb 2020, submitted).
• Chen E, Monnette A, Bazzano A, Hong D, Dixon SE, Arnold WD, Shi, L, “Preference of treatment characteristics among patients with spinal muscular atrophy (SMA): A discrete choice experiment”. AAN Annual Meeting, Toronto, Canada (April-May 2020, submitted).
• Arnold, WD., Chen, E., Naik, R., Noone, J., Whitmire, S., Buchenberger, D., Dixon, S.E. (in preparation). Clinical Experience of Spinal Muscular Atrophy (SMA) Treatment: Physician’s Perspective. Muscle & Nerve.
• Dixon, S.E., Chen E., Naik, R., Noone, J., Buchenberger, D., Whitmire, S., Arnold, WD. (in preparation). Early experiences in the Treatment of Spinal Muscular Atrophy: Results from a large survey of patients and caregivers. Muscle & Nerve.
• Chen, E., Bawa, K., Noone, J., Whitmire, S., Buchenberger, D., Arnold, WD., Dixon, S.E. (in preparation). Impact of Spinal Muscular Atrophy on Caregivers’ Daily Activities and Health-related Quality of Life. Journal of Orphanet.
• Arnold, WD., Chen, E., Naik, R., Noone, J., Whitmire, S., Buchenberger, D., Dixon, S.E. Clinical Experience of Spinal Muscular Atrophy (SMA) Treatment: Physician’s Perspective.
• Chen E., Naik, R., Noone, J., Buchenberger, D., Whitmire, Dixon, S.E, S., Arnold, WD. Early experiences in the Treatment of Spinal Muscular Atrophy: Results from a large survey of patients and caregivers.
• Chen, E., Bawa, K., Noone, J., Whitmire, S., Buchenberger, D., Arnold, WD., Dixon, S.E. Impact of Spinal Muscular Atrophy on Caregivers’ Daily Activities and Health-related Quality of Life.
• Monnette, A., Chen, E., Hong, D., Bazzano, A., Dixon, S., Arnold, WD., Shi, L., Treatment Preference among Patients with Spinal Muscular Atrophy (SMA): A Discrete Choice Experiment.
• Hewamadduma C, Ouillade L, Kunkel DC, Scoto M, Chiriboga CA, Dai Y, Dixon S, Gómez García de la Banda M, Laverty CG, Lemmetty PK, Parson J, Samarji B, Sansone VA, Servais L, Korb MK. International Modified Delphi Consensus on the Management of Diarrhea in Patients with Spinal Muscular Atrophy Treated with Risdiplam.
• Hunn SM, Findlay A, Alfano LN, Jones A, Butler A, Lowes LP, Iammarino MA, Reash NF, Pietruszewski L, Sasidharan S, Currence M, Statland JM, Strahler T, Will R, Wicklund M, Dixon S, Augsburger R, Mozaffar T, Laubscher KM, Mockler SRH, Matthews KD, Stinson N, Leung DG, Stark MM, Horton RA, Kang PB, James MK, Clause A, Weihl CC, Johnson NE, and the GRASP-LGMD Consortium. Natural History of Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study.
• Henriquez A, Dixon S, Duong T, Culhane Maravic M, Cagle C, Jamaleddine A, Brown T, Cherubino C, Gueye M, Stanley-Copeland A, Nelson L. “Meaningfulness of ‘any point change’ in the HFMSE on the psychosocial well-being of adult patients with spinal muscular atrophy.” Submitted to MDA Clinical & Scientific Conference in March 2026 in Orlando, Florida
• Henriquez A, Dixon S, Duong T, Land N, Jamaleddine A, Brown T, Cherubino C, Gueye M, Stanley-Copeland A, Nelson L. “Understanding adult patient perspectives on the clinical meaningfulness of ‘any point differences’ on the Hammersmith Functional Motor Scale-Expanded in SMA. Accepted for a poster presentation at the TREAT-NMD International Congress in February 2026 in Lisbon, Portugal.
• Henriquez A, Dixon S, Duong T, Culhane Maravic M, Cagle C, Brown T, Cherubino C, Gueye M, Stanley-Copeland A, Nelson L. “Assessing the impact of ‘any point differences or ‘stability’ in the Hammersmith Functional Motor Scale-Expanded on activities of daily living in adult patients with SMA.” Accepted for a poster presentation at the TREAT-NMD International Congress in February 2026 in Lisbon, Portugal.
• Venezia GA, Dixon S, Lafreniere M, Fridman V. “A novel cause of motor neuropathy with conduction blocks in a young woman.” Submitted to 48th Annual Carrell Krusen Neuromuscular Symposium in February 2026 in Dallas, Texas.
• Goyal NA, Machado PM, Ascherman DP, Benveniste O, Beydoun SR, Brannagan III TH, Caress JB, Christopher-Stein L, Collins MP, De Bleecker JL, Dimachkie M, Dixon S, Dmitrienko A, Fernandex DR, Freimer M, Geiger C, Gonzalez-Perez P, Goyal N, Gwathmey K, Heitzman D, Henderson R, Hobson-Webb LD, Hussain Y, Korngut L, Liang C, Lilleker JB, Lloyd T, Mohassel P, Naddaf E, Needham M, Piccione E, Quinn CC, Rosow L, Roy B, Ruck T, Schmidt J, Seth A, Shah J, Shaibani A, Shieh PB, Simmons Z, Kumaraswamy S, Wang LH, Weihl CC, Wilkins HJ, Amato AA. “Phase 2/3 Study of Ulviprubart in Inclusion Body Myositis: Study Design, Patient Characteristics, and Topline Results.” Submitted to 6th Global Conference on Myositis, March 2026 in Lisbon, Portugal.
• Hunn SM, Goyal N, Amaot A, Shieh PB, Freimer M, Dimachkie M, Wang LH, Wicklund M, Dixon S, Shaibani A,Lloyd TE, Mohassel P, Quinn C, Chahin N, Carbunar O, Weihl CC, Tawil R, Ciafoloni E, The INSPIRE-IBM Study Group, and Mozafar T. “Exploring relationships between the IBMFRS and transitional ambulatory phases and the impact of fall risk in patients with Inclusion Body Myositis (IBM): INSPIRE-IBM.” Submitted to 6th Global Conference on Myositis, March 2026 in Lisbon, Portugal.
• Goyal NA, Machado PM, Ascherman DP, Benveniste O, Beydoun SR, Brannagan III TH, Caress JB, Christopher-Stein L, Collins MP, De Bleecker JL, Dimachkie M, Dixon S, Dmitrienko A, Fernandex DR, Freimer M, Geiger C, Gonzalez-Perez P, Goyal N, Gwathmey K, Heitzman D, Henderson R, Hobson-Webb LD, Hussain Y, Korngut L, Liang C, Lilleker JB, Lloyd T, Mohassel P, Naddaf E, Needham M, Piccione E, Quinn CC, Rosow L, Roy B, Ruck T, Schmidt J, Seth A, Shah J, Shaibani A, Shieh PB, Simmons Z, Kumaraswamy S, Wang LH, Weihl CC, Wilkins HJ, Amato AA. “Phase 2/3 Study of Ulviprubart in Inclusion Body Myositis: Study Design, Patient Characteristics, and Topline Results.” Submitted to 19th International Congress on Neuromuscular Diseases, July 2026 in Florence, Italy.

Practice Locations

UCHealth Neurosciences Center - Anschutz Medical Campus
1635 Aurora Ct
4th Floor
Aurora, CO 80045
720-848-2080

UCHealth Anschutz Outpatient Pavilion - Anschutz Medical Campus
1635 Aurora Ct
Aurora, CO 80045
720-848-0000

Rocky Mountain Regional Veterans Administration Medical Center
1700 Wheeling St
Aurora, CO 80045
303-399-8020

Hospital Affiliation

• University of Colorado Hospital
• Veterans Affairs Medical Center

Specialty Information

Specialties

• Neurology, Board Certification
• Neuromuscular Medicine

Conditions & Treatments

• Brain and Nervous System - Neuromuscular Diseases
• Brain and Nervous System